38 A phase 3 trial including adults with T2DM receiving orforglipron daily (3 mg, 12 mg or 36 mg) showed significant placebo-adjusted reductions in HbA 1c (1.07%) and weight loss (5.9%) at the highest dose
We are thankful to Dr Jean Kim and the Human Stem Cell Core at Baylor College of Medicine for mediating the cell transfer, Dr Tobias Dick for Grx1-roGFP2 plasmid, and Drs Vsevolod Belousov, Luke Lavis, and Catherine Goodman for thoughtful discussions
What new research on GLP-1s and migraines found In a 12-week study published in Headache: The Journal of Head and Face Pain , researchers tracked adults living with both obesity and chronic migraines who added the GLP-1 medication liraglutide (brand name Victoza) to their usual migraine treatment
Understanding your biomarker profile helps providers tailor dosing, monitor for adverse effects, and adjust therapy if needed during your treatment course
Nutrient combinations In addition to the monotherapies described above, some clinical trials have studied the effects of multi-component nutrient formulations (nutrient combinations)
